+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Latent TB Testing Market by Product Type (Instruments, Kits, Reagents), Test Type (Interferon Gamma Release Assays (IGRAs), Tuberculin Skin Test (TST)), Application, End User - Global Forecast 2025-2030- Product Image
Latent TB Testing Market by Product Type (Instruments, Kits, Reagents), Test Type (Interferon Gamma Release Assays (IGRAs), Tuberculin Skin Test (TST)), Application, End User - Global Forecast 2025-2030- Product Image
Sale

Latent TB Testing Market by Product Type (Instruments, Kits, Reagents), Test Type (Interferon Gamma Release Assays (IGRAs), Tuberculin Skin Test (TST)), Application, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055453
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Latent TB Testing Market grew from USD 1.32 billion in 2024 to USD 1.39 billion in 2025. It is expected to continue growing at a CAGR of 5.70%, reaching USD 1.84 billion by 2030.

The latent tuberculosis (TB) testing market has evolved into a sophisticated arena driven by scientific breakthroughs, heightened regulatory standards, and the global emphasis on public health initiatives. In recent years, this market has witnessed rapid technological advancements that have enabled more accurate and reliable testing methods. Ongoing research, improved diagnostic protocols, and strong public health policies are fueling the demand for innovative testing solutions.

The complexity of latent TB, characterized by its asymptomatic nature and potential for reactivation, requires a nuanced approach for detection and prevention. As countries strive to meet global health targets, stakeholders are increasingly investing in diagnostics that offer higher sensitivity and specificity. This introductory analysis sets the stage for a deeper exploration of market trends, segmentation frameworks, regional dynamics, key companies, and strategic recommendations by providing a comprehensive overview of factors influencing the latent TB testing landscape.

Through this detailed examination, the narrative not only highlights the current state of the industry but also identifies evolving areas that have the potential to redefine market trajectories. The insights presented here serve as a guide for decision-makers and experts, emphasizing the critical need for advanced testing methodologies in combating latent TB effectively.

Transformative Shifts in the Landscape: Pioneering Changes and Strategic Evolution

Over the past decade, the latent TB testing market has undergone transformative shifts that have fundamentally altered its landscape. Breakthroughs in diagnostic technology, regulatory advancements, and evolving healthcare infrastructures have collectively contributed to reimagining latent TB detection methods. These paradigm shifts are not only reshaping diagnostic protocols but also expanding the scope for research and development in this crucial area.

Key technological innovations have redefined testing accuracy by introducing automated, high-throughput systems that enable laboratories to process large volumes of tests with improved precision. Such advancements have directly impacted turnaround times, significantly reducing the gap between sample collection and diagnosis. Regulatory changes have further streamlined the process for the introduction of new testing devices by fostering a more collaborative environment between product developers and health authorities.

Furthermore, the increasing integration of digital health platforms is providing unprecedented opportunities for data analytics, facilitating real-time monitoring of testing outcomes and infection trends. As the industry continues to innovate, this convergence of technology, policy, and market demand is propelling the latent TB testing sector into a new era marked by efficiency, precision, and accessibility. The strategic realignment of resources towards advanced, user-friendly diagnostic methods signals a promising shift toward a more responsive and resilient healthcare system.

Key Segmentation Insights: Dissecting Market Dynamics for Targeted Analysis

An in-depth segmentation analysis offers crucial insights into the latent TB testing market by addressing multiple dimensions that underline commercial and clinical decision-making. The market is segmented based on product type, test type, application, and end user. When evaluating product type, the analysis is performed across instruments, kits, and reagents, which collectively define the range of diagnostic solutions available to both clinical and research settings. This granularity aids in identifying areas with the greatest demand and technological growth potential.

Focusing on test type further refines the market segmentation into interferon gamma release assays (IGRAs) and tuberculin skin tests (TST). The IGRA category is further differentiated into chemiluminescence and enzyme-linked immunosorbent assay (ELISA) techniques, each offering unique advantages in terms of sensitivity and workflow integration. In contrast, the TST category splits into intradermal and multipuncture methods, underscoring subtle differences that can influence diagnostic choices based on clinical scenarios.

Additional insights emerge when the market is segmented by application, which encompasses diagnostic testing, research, and screening. Within research, new test development and vaccine development act as critical drivers for innovation, whereas health check-ups and immigration screening are key components in the screening segment. Understanding these intricate subdivisions is essential for stakeholders aiming to capitalize on niche market segments. The segmentation by end user further considers diagnostic centres, hospital laboratories, public health departments, and research institutes, each reflecting distinct procurement behaviors and technological requirements that tailor the overall market strategy.

Based on Product Type, market is studied across Instruments, Kits, and Reagents.

Based on Test Type, market is studied across Interferon Gamma Release Assays (IGRAs) and Tuberculin Skin Test (TST). The Interferon Gamma Release Assays (IGRAs) is further studied across Chemiluminescence and ELISA (Enzyme-Linked Immunosorbent Assay). The Tuberculin Skin Test (TST) is further studied across Intradermal and Multipuncture.

Based on Application, market is studied across Diagnostic Testing, Research, and Screening. The Research is further studied across New Test Development and Vaccine Development. The Screening is further studied across Health Check-Ups and Immigration Screening.

Based on End User, market is studied across Diagnostic Centres, Hospital Laboratories, Public Health Departments, and Research Institutes.

Key Regional Insights: Navigating Global Market Dynamics

Examining the latent TB testing market through the lens of regional insights reveals notable variations and opportunities that mirror the complexities of global healthcare landscapes. In the Americas, stringent health policies and high standards in diagnostic accuracy create a robust demand for advanced latent TB testing solutions. An environment that favors technological integration and proactive public health measures has positioned this region as a pivotal market for next-generation testing methodologies.

In the combined region of Europe, Middle East & Africa, the market paints a diverse picture. European markets are characterized by well-established regulatory frameworks that support innovation and enforce high quality, while the Middle East consistently seeks advanced diagnostic capabilities to tackle emerging health threats. Africa, facing distinct challenges such as resource constraints and a high TB burden, is increasingly investing in scalable and cost-effective diagnostic technologies to improve healthcare outreach.

Asia-Pacific markets, on the other hand, are emerging as hotspots for growth fueled by rapid urbanization, expanding healthcare infrastructure, and government-led health initiatives. The region’s emphasis on both quality and quantity in diagnostic services has fostered an environment where innovative testing technologies are increasingly adopted. This regional diversity underscores the need for tailored market strategies that harmonize with local economic and regulatory settings while ensuring a balanced approach to innovation and accessibility.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Profiling Industry Leaders and Innovators

The latent TB testing market is spearheaded by a range of prominent companies that have consistently set benchmarks in terms of technological innovation and market leadership. Industry giants such as Abbott Laboratories, Beckman Coulter, Inc. and Becton, Dickinson and Company (BD) continue to lead with extensive portfolios that address diverse testing needs. These companies are supported by influential players including Bio-Rad Laboratories, Inc., Biocare Medical, LLC, and bioMérieux SA, all of whom have forged strong reputations for reliability and technical excellence.

Companies such as Cepheid, Inc. and Danaher Corporation have carved out distinctive market segments by prioritizing research, development, and streamlined diagnostic procedures that enhance throughput and accuracy. Further, DiaSorin S.p.A. and Eiken Chemical Co., Ltd. have brought pioneering solutions to the forefront that resonate with both clinical applications and public health strategies.

Additional leaders driving the industry include ElitechGroup SAS by Bruker Company, F. Hoffmann-La Roche AG, and Fujifilm Holdings Corporation, each contributing significantly to market expansion through innovative product offerings and strategic partnerships. Other influential companies such as Hologic, Inc., Mabtech AB, and Meridian Bioscience, Inc. are reshaping market dynamics by focusing on precision and accessibility. The market is further enriched by the forward-thinking approaches of Oxford Immunotec Limited by PerkinElmer, Inc., Qiagen N.V., as well as Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Bioscience, Inc., whose contributions underscore an industry-wide commitment to reliable, state-of-the-art diagnostic technology.

The report delves into recent significant developments in the Latent TB Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Biocare Medical, LLC, bioMérieux SA, Cepheid, Inc., Danaher Corporation, DiaSorin S.p.A., Eiken Chemical Co., Ltd., ElitechGroup SAS by Bruker Company, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Hologic, Inc., Mabtech AB, Meridian Bioscience, Inc., Oxford Immunotec Limited by PerkinElmer, Inc., Qiagen N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Bioscience, Inc..

Actionable Recommendations: Strategic Steps for Industry Leaders

Industry leaders must adopt a forward-thinking strategy that integrates technological innovation with robust market insight to capture the opportunities presented by the evolving latent TB testing landscape. The data suggests investing in research and development, particularly in emerging areas like automated diagnostic systems and digital health integration, which promise to enhance both efficiency and precision. Staying abreast of regulatory changes and fostering close collaboration with health authorities will ensure that new products meet stringent safety and efficacy standards, thereby streamlining market entry and adoption.

To gain a competitive edge, companies should invest in building scalable platforms that are adaptable to varying regional demands, thereby bridging technological gaps across diverse healthcare ecosystems. Embracing partnerships and collaborative ventures will amplify access to fresh insights and innovative technologies. Strategic diversification into related segments such as vaccine development and novel assay formats presents a lucrative opportunity to expand service portfolios and drive sustained growth.

Furthermore, leveraging advanced data analytics to anticipate market trends and guide strategic investments in precision diagnostics and automated workflows is key. Industry leaders are encouraged to develop comprehensive training programs for clinicians and laboratory personnel, ensuring smooth adoption of cutting-edge technologies. By aligning operational efficiencies with global health initiatives, organizations can create resilient strategies that foster both technological progress and improved public health outcomes.

Synthesizing Insights for Informed Decision-Making

The comprehensive analysis of the latent TB testing market underscores a dynamic environment characterized by innovation, segmentation diversity, and regional variances in demand. Collectively, the insights reveal a market that is not only poised for growth but is also driven by strategic investments in automation, regulatory alignment, and scientific research. The convergence of technology and public health imperatives is paving the way for groundbreaking diagnostic solutions that address the nuanced challenges posed by latent TB.

This synthesis of data and expert analysis reinforces the importance of staying agile in the face of evolving market forces. For decision-makers, the key takeaway is the critical need to embrace innovation while carefully navigating regional and sector-specific complexities. By doing so, stakeholders can effectively position themselves to capitalize on the impressive growth prospects and address emerging challenges within the global healthcare landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing penetration of latent TB testing in rural and underserved areas through mobile clinics
5.1.1.2. Increasing prevalence of diseases that weaken the immune system increasing susceptibility to TB infection
5.1.1.3. Rising awareness about latent tuberculosis infections among at-risk populations and healthcare providers
5.1.2. Restraints
5.1.2.1. Analyzing the impact of high costs and limited funding on latent TB testing accessibility and expansion
5.1.3. Opportunities
5.1.3.1. Technological advancements in TB testing methods enhancing speed, accuracy, and accessibility
5.1.3.2. Collaborations between public and private sectors strengthening the latent TB diagnostic market
5.1.4. Challenges
5.1.4.1. Inconsistent government policies and regulations across different countries or regions
5.2. Market Segmentation Analysis
5.2.1. Test Type: Utilization in tuberculin skin testing for enhancing accuracy and accessibility
5.2.2. End User: Adoption in latent TB testing for hospital laboratories due to advanced technologies
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Latent TB Testing Market, by Product Type
6.1. Introduction
6.2. Instruments
6.3. Kits
6.4. Reagents
7. Latent TB Testing Market, by Test Type
7.1. Introduction
7.2. Interferon Gamma Release Assays (IGRAs)
7.2.1. Chemiluminescence
7.2.2. ELISA (Enzyme-Linked Immunosorbent Assay)
7.3. Tuberculin Skin Test (TST)
7.3.1. Intradermal
7.3.2. Multipuncture
8. Latent TB Testing Market, by Application
8.1. Introduction
8.2. Diagnostic Testing
8.3. Research
8.3.1. New Test Development
8.3.2. Vaccine Development
8.4. Screening
8.4.1. Health Check-Ups
8.4.2. Immigration Screening
9. Latent TB Testing Market, by End User
9.1. Introduction
9.2. Diagnostic Centres
9.3. Hospital Laboratories
9.4. Public Health Departments
9.5. Research Institutes
10. Americas Latent TB Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Latent TB Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Latent TB Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2024
13.2. FPNV Positioning Matrix, 2024
13.3. Competitive Scenario Analysis
13.3.1. U.S. launch of SIMLANDI Teva and Alvotech's strategic biosimilar milestone
13.3.2. Revvity introduces advanced automation in latent TB testing with auto-pure 2400
13.3.3. QIAGEN enhances tuberculosis testing portfolio with new NGS panel for improved surveillance
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. LATENT TB TESTING MARKET MULTI-CURRENCY
FIGURE 2. LATENT TB TESTING MARKET MULTI-LANGUAGE
FIGURE 3. LATENT TB TESTING MARKET RESEARCH PROCESS
FIGURE 4. LATENT TB TESTING MARKET SIZE, 2024 VS 2030
FIGURE 5. GLOBAL LATENT TB TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL LATENT TB TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 9. GLOBAL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 11. GLOBAL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 13. GLOBAL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL LATENT TB TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 15. GLOBAL LATENT TB TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 16. AMERICAS LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 17. AMERICAS LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 18. UNITED STATES LATENT TB TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 19. UNITED STATES LATENT TB TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 20. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 21. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 24. LATENT TB TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 25. LATENT TB TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LATENT TB TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LATENT TB TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LATENT TB TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. LATENT TB TESTING MARKET DYNAMICS
TABLE 7. GLOBAL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LATENT TB TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LATENT TB TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LATENT TB TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LATENT TB TESTING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LATENT TB TESTING MARKET SIZE, BY ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAY), BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LATENT TB TESTING MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LATENT TB TESTING MARKET SIZE, BY MULTIPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LATENT TB TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LATENT TB TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LATENT TB TESTING MARKET SIZE, BY NEW TEST DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LATENT TB TESTING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LATENT TB TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LATENT TB TESTING MARKET SIZE, BY HEALTH CHECK-UPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LATENT TB TESTING MARKET SIZE, BY IMMIGRATION SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LATENT TB TESTING MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LATENT TB TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LATENT TB TESTING MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL LATENT TB TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 38. AMERICAS LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 39. AMERICAS LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 55. BRAZIL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 56. BRAZIL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 62. CANADA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 63. CANADA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 64. CANADA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 66. CANADA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 67. CANADA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 71. MEXICO LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 72. MEXICO LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 74. MEXICO LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 75. MEXICO LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES LATENT TB TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 92. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 100. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 101. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. CHINA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. CHINA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 104. CHINA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 105. CHINA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 106. CHINA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. CHINA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 108. CHINA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 109. CHINA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. INDIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 111. INDIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 112. INDIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 113. INDIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 114. INDIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 115. INDIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 116. INDIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 117. INDIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 121. INDONESIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 122. INDONESIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 124. INDONESIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 125. INDONESIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. JAPAN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. JAPAN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 128. JAPAN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 129. JAPAN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 130. JAPAN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. JAPAN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 132. JAPAN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 133. JAPAN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. MALAYSIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. MALAYSIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 140. MALAYSIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 141. MALAYSIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 143. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 148. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 149. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. SINGAPORE LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 151. SINGAPORE LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 156. SINGAPORE LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 157. SINGAPORE LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 164. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 165. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. TAIWAN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. TAIWAN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 169. TAIWAN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 170. TAIWAN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 172. TAIWAN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 173. TAIWAN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. THAILAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. THAILAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 176. THAILAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 177. THAILAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 178. THAILAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. THAILAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 180. THAILAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 181. THAILAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 185. VIETNAM LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 186. VIETNAM LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 188. VIETNAM LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 189. VIETNAM LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 199. DENMARK LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 200. DENMARK LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 201. DENMARK LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 202. DENMARK LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 203. DENMARK LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. DENMARK LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 205. DENMARK LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 206. DENMARK LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. EGYPT LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 208. EGYPT LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 209. EGYPT LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 210. EGYPT LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 211. EGYPT LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. EGYPT LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 213. EGYPT LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 214. EGYPT LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. FINLAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 216. FINLAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 217. FINLAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 218. FINLAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 219. FINLAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 220. FINLAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 221. FINLAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 222. FINLAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. FRANCE LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 224. FRANCE LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 225. FRANCE LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 226. FRANCE LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 227. FRANCE LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. FRANCE LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 229. FRANCE LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 230. FRANCE LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 231. GERMANY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. GERMANY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 233. GERMANY LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 234. GERMANY LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 235. GERMANY LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 236. GERMANY LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 237. GERMANY LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 238. GERMANY LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 242. ISRAEL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 243. ISRAEL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 245. ISRAEL LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 246. ISRAEL LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. ITALY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. ITALY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 249. ITALY LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 250. ITALY LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 251. ITALY LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. ITALY LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 253. ITALY LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 254. ITALY LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 261. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 262. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 266. NIGERIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 267. NIGERIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. NORWAY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 274. NORWAY LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 275. NORWAY LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. NORWAY LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 277. NORWAY LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 278. NORWAY LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. POLAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 280. POLAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 281. POLAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 282. POLAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 283. POLAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. POLAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 285. POLAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 286. POLAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. QATAR LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 288. QATAR LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 289. QATAR LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 290. QATAR LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 291. QATAR LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 292. QATAR LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 293. QATAR LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 294. QATAR LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 298. RUSSIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 299. RUSSIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 301. RUSSIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 302. RUSSIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 310. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 314. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 316. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 318. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. SPAIN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. SPAIN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 321. SPAIN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 322. SPAIN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 323. SPAIN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 324. SPAIN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 325. SPAIN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 326. SPAIN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 330. SWEDEN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 331. SWEDEN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 335. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 336. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 337. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
TABLE 338. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
TABLE 339. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 340. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
TABLE 341. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
TABLE 342. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 343. TURKEY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 344. TURKEY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 345. TURK

Companies Mentioned

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company (BD)
  • Bio-Rad Laboratories, Inc.
  • Biocare Medical, LLC
  • bioMérieux SA
  • Cepheid, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Eiken Chemical Co., Ltd.
  • ElitechGroup SAS by Bruker Company
  • F. Hoffmann-La Roche AG
  • Fujifilm Holdings Corporation
  • Hologic, Inc.
  • Mabtech AB
  • Meridian Bioscience, Inc.
  • Oxford Immunotec Limited by PerkinElmer, Inc.
  • Qiagen N.V.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Tosoh Bioscience, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedMarch 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.39 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.84 Billion
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Latent TB Testing Market (2025 Edition): Analysis By Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA)), By End User, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Latent TB Testing Market (2025 Edition): Analysis By Test Type (Tuberculin Skin Test (TST), and Interferon Gamma Released Assay (IGRA)), By End User, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 198 Pages
  • Global
From
Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living With HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029 - Product Image

Latent TB Testing Market by Test Type (Tuberculin Skin Test/TST, IGRA Test), Application (Household Contacts (HHC) of Tuberculosis (TB) Patients, People Living With HIV), End User (Diagnostic Labs, Hospitals), Region - Global Forecast to 2029

  • Report
  • 261 Pages
  • Global
From
Latent TB Diagnostics Market 2025-2029 - Global Market Analysis and Forecasts by Assay, Risk Factor, and Lab/Place, with Executive and Consultant Guides - Product Image

Latent TB Diagnostics Market 2025-2029 - Global Market Analysis and Forecasts by Assay, Risk Factor, and Lab/Place, with Executive and Consultant Guides

  • Report
  • 322 Pages
  • Global
From
Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand (QFT-Plus), Test Type, Application, End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report by Brand (QFT-Plus), Test Type, Application, End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Tuberculosis Testing Market by Test, Indication, Testing Location, End User - Global Forecast 2025-2030 - Product Image

Tuberculosis Testing Market by Test, Indication, Testing Location, End User - Global Forecast 2025-2030

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.